Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

iBio bolsters immuno-oncology pipeline with RubrYc Therapeutics alliance

Biopharma iBio has entered into a definitive global exclusive license agreement for RTX-003, an immunotherapy candidate targeting regulatory T cells.

By Brian Buntz | August 26, 2021

iBio-RubrYcBiopharma iBio, Inc. (NYSEA:IBIO) has entered into a definitive global exclusive license agreement with RubrYc Therapeutics for RTX-003, an immunotherapy candidate targeting regulatory T cells. In addition, the deal includes an option for iBio to license additional antibodies designed with RubrYc’s antibody discovery platform based on machine learning and computational biology.

iBio made an upfront $5 million payment to RubrYc for the rights and has committed to an additional $2.5 million payment in December 2021. iBio will have the rights to commercialize RTX-003 and has retained options for other molecules developed with RubrYc’s predictive algorithms. The deal also includes an equity stake. RubrYc is eligible to receive certain pre-specified payments upon achievement of development milestones for IBIO-101, as well as royalties on net sales of that molecule and other licensed antibodies.

RTX-003 binds to interleukin-2 (IL-2) receptor alpha chain (CD25) without interfering with the IL-2 signaling pathway. Enabling that functionality is “a widely recognized challenge,” said Tom Isett, chairman and CEO of iBio, in a statement. The preclinical development of RTX-003 thus validates the functionality of RubrYc. “Moving forward, we aim to replicate this discovery and development model by combining access to the RubrYc Discovery Platform with iBio’s proprietary Glycaneering and FastPharming Technologies to bring multiple new candidates to the clinic in a timely and cost-efficient manner,” he added.

iBio’s FastPharming uses a plant-based system rather than a traditional mammalian system.

iBio

Image courtesy of iBio

“By avoiding lengthy cell-line engineering requirements of traditional mammalian cell bioprocessing, FastPharming enables more candidates to reach early preclinical and IND-enabling studies faster,” said iBio Chief Operating Officer Randy Maddux. “The time and money saved on early development ultimately gets the right candidate to the clinic sooner, and in a more sustainable production system than traditional methods.”

iBio says FastPharming technology can yield a few milligrams of material for feasibility testing in approximately five weeks. 

The GMP scale-up process for FastPharming uses bacteria for the engineering and qualification of the master cell bank. With the mammalian process, the engineering, qualification and GMP production times are longer, according to iBio.

As opposed to traditional cell-culture bioprocesses that are often performed using plastic, single-use bioreactor systems, iBio’s FastPharming System uses plants as bioreactors. 

A plant-specific expression vector with the gene of interest is transfected into Agrobacterium, which is then vacuum-infiltrated into the leaves of the company’s proprietary Nicotiana benthamiana plants, which is a tobacco relative. The target protein is expressed in the leaves as the plants grow. The company then harvests the leaves, and isolates and purifies the protein. It can then be formulated into the desired final product.

RubrYc Therapeutics created RTX-003 to induce T regulatory cell death to enhance the immune response to tumors. Increased T reg cells or decreased active T cells in a tumor are linked with reduced overall survival and progression-free survival in various tumors.

iBio plans to bring RTX-003 to the clinic as IBIO-101, using its FastPharming System to produce the drug candidate.

The company hopes to launch IND-enabling studies by mid-2022.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: FastPharming, iBio, RTX-003, RubrYc Therapeutics
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE